The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction

被引：120

作者：

Greene, Stephen J. ^{[1
]}

Gheorghiade, Mihai ^{[1
]}

Borlaug, Barry A. ^{[2
]}

Pieske, Burkert ^{[3
]}

Vaduganathan, Muthiah ^{[4
]}

Burnett, John C., Jr. ^{[2
]}

Roessig, Lothar ^{[5
]}

Stasch, Johannes-Peter ^{[6
]}

Solomon, Scott D. ^{[7
]}

Paulus, Walter J. ^{[8
]}

Butler, Javed ^{[9
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA

[2] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN USA

[3] Med Univ Graz, Dept Cardiol, Graz, Austria

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA

[5] Bayer Pharma AG, Berlin, Germany

[6] Bayer HealthCare, Cardiol Res, Wuppertal, Germany

[7] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA

[8] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Physiol, Inst Cardiovasc Res VU, Amsterdam, Netherlands

[9] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA

来源：

JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2013年 / 2卷 / 06期

关键词：

cGMP; heart failure; phosphodiesterase; 5; preserved ejection fraction; soluble guanylate cyclase; SOLUBLE GUANYLATE-CYCLASE; NITRIC-OXIDE SYNTHASE; IMPROVES EXERCISE CAPACITY; PULMONARY-HYPERTENSION; NATRIURETIC PEPTIDE; PHOSPHODIESTERASE-5; INHIBITION; DIASTOLIC DISTENSIBILITY; ENDOTHELIAL DYSFUNCTION; SODIUM-NITROPRUSSIDE; CONTRACTILE RESPONSE;

D O I：

10.1161/JAHA.113.000536

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：11

共 50 条

[1] Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?
Kovacs, A.
Alogna, A.
Post, H.
Hamdani, N.
NETHERLANDS HEART JOURNAL, 2016, 24 (04) : 268 - 274
[2] Treatment of Heart Failure with Preserved Ejection Fraction
Iliesiu, Adriana Mihaela
Hodorogea, Andreea Simona
HEART FAILURE: FROM RESEARCH TO CLINICAL PRACTICE, VOL 3, 2018, 1067 : 67 - 87
[3] Inflammation as a therapeutic target in heart failure with preserved ejection fraction
Peh, Zhen Hui
Dihoum, Adel
Hutton, Dana
Arthur, J. Simon C.
Rena, Graham
Khan, Faisel
Lang, Chim C. C.
Mordi, Ify R.
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
[4] Heart Failure with Preserved Ejection Fraction: Emerging Drug Strategies
Zouein, Fouad A.
Bras, Lisandra E. de Castro
da Costa, Danielle V.
Lindsey, Merry L.
Kurdi, Mazen
Booz, George W.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 62 (01) : 13 - 21
[5] Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, Carolyn S. P.
Voors, Adriaan A.
de Boer, Rudolf A.
Solomon, Scott D.
van Veldhuisen, Dirk J.
EUROPEAN HEART JOURNAL, 2018, 39 (30) : 2780 - 2792
[6] Pulmonary hypertension in heart failure with preserved ejection fraction
Guazzi, Marco
Gomberg-Maitland, Mardi
Arena, Ross
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (03) : 273 - 281
[7] Heart failure with preserved ejection fraction: a clinical dilemma
Komajda, Michel
Lam, Carolyn S. P.
EUROPEAN HEART JOURNAL, 2014, 35 (16) : 1022 - +
[8] Heart failure with preserved left ventricular ejection fraction
Petutschnigg, Johannes
Edelmann, Frank
INTERNIST, 2019, 60 (09): : 925 - 942
[9] Management of Heart Failure With Preserved Ejection Fraction: A Review
Nanayakkara, Shane
Kaye, David M.
CLINICAL THERAPEUTICS, 2015, 37 (10) : 2186 - 2198
[10] Current Therapeutic Approach in Heart Failure with Preserved Ejection Fraction
Nativi-Nicolau, Jose
Ryan, John J.
Fang, James C.
HEART FAILURE CLINICS, 2014, 10 (03) : 525 - +

← 1 2 3 4 5 →